Ekf Diagnostics Share Discussion Threads

[sirshagalot] 27/8/2021 15:45

EKF GOING UP

[rivaldo] 27/8/2021 15:30

Good to see the share price consolidating at 80p and above. About ready for a push upwards before the results on 14th September methinks.

[mg1982] 27/8/2021 14:11

Not at all Mr Tongster, not at all. I've got a bit longer time horizon than you.

Still waiting for you to claim to be in this before it goes up. You must have lost a lot of money trading this to be still around despite so many other easier trades

[tongosti] 27/8/2021 13:05

Our clueless friend Mg must be really praying for a breakout isn't he. Been a long wait for him innit

[wan] 27/8/2021 09:08

I have no idea what market share PrimeStore has, but given the attributes, in certain applications it would attain a high market share.

Question (b) and (c) will need to be addressed by EKF, as I don't know the specific answer.

However, in a sort of answer to question (b) what I do know from a question that I previously asked, was that EKF are the only manufacturer and supplier of the most important, patented and closely guarded ingredients for PrimeStore MTM.

And if still correct, this could matter even more now that the benefits and attributes of the patent protected PrimeStore MTM have been realised and widely recognised globally. And if other players get permission from Longhorn to launch similar versions/replication of PrimeStore MTM, then the volumes of closely guarded ingredients produced by EKF could materially increase.

In another sort of answer to (c), PBS is not a Longhorn/PrimeStore related product, and for which I think turnover will prove to be very high as it is being used in various collection kits in the US, UK and Europe. PBS solution was introduced into the market Q4 2020, and due to an increase in demand, additional production lines for Phosphate Buffered Saline (PBS) were established Q1 2021 at Boerne, South Bend, Barleben and Cardiff sites.

It's also worth considering that PBS (and MTM & ATM) has application for testing 'beyond' Covid collection kits.

[pldazzle] 27/8/2021 08:19

Many thanks wan, that's helpful. For transport media/sample collections products, would you know (a) what market share PrimeStore has, (b) roughly what percentage of PrimeStore's transport media EKF manufactures i.e. how much are EKF's competitors responsible for, (c) what percentage of EKF's transport media turnover (if any) is non-PrimeStore related?

And: Any thoughts on SBI?

[wan] 27/8/2021 07:28

pldazzle...PBS and MTM (and ATM) are sample transport mediums/sample collection products contained in a collection tube into which a sample swab is inserted, they are not tests in themselves and are thus transported to labs for testing. Thus they are included within test 'collection' kits for lab PCR testing, including use in test to travel and tests to release kits, including via sample collection/drive-through etc.

I am not an expert, but fwiw here is a short explanation of my understanding -

PBS is Phosphate Buffered Saline used for sample collection, ultimately used for PCR lab testing. Phosphate Buffered Saline offers advantages over say PrimeStore MTM in terms of supply chain logistics and ease of use due to the absence of potentially hazardous preservative fluid. Thus, PBS is used for direct-to-consumer 'self-collect' kits as it is a non-toxic solution. Swabs in PBS can be transported and stored at between -20°C and +40°C for up to 120 hours (5 days) thus in certain circumstances cold chain storage and transportation is required prior to lab testing.

PrimeStore MTM is an inactivation transport medium also for PCR lab testing, and is better utilised when the sample is not self-collected, or in a situation where infection control is perhaps more difficult or absent, and/or where cold chain logistics is not available, and where it may be difficult for the labs to achieve the appropriate or required Biosafety Level.


PrimeStore ATM is a new product optimised for molecular testing (such as PCR) that is not yet commercially available and is currently for research use only, so details are still limited. PrimeStore ATM is a sample collection device that also inactivates viruses, but importantly it does not contain the ingredients that would classify it as toxic, it also enables an extraction-free process which is usually required for molecular tests such as PCR. Apparently, ATM can also enable highly sensitive antigen testing capabilities, which in my book means that it may have important utility in 'enabling' rapid testing such as point-of-care testing. Time will tell.


Molecular Transport Media

[wan] 27/8/2021 05:02

Boadicea...I already own Trellus shares in my ISA (Ordinary Shares). So, I think that that note is because currently they are A shares (the dividend or entitlement shares held in trust), but the A shares will automatically convert into ordinary shares in Trellus on the basis of one Ordinary Share for each A Share on admission to trading on AIM, so I cannot see any reason either why they will not be eligible.

[pldazzle] 26/8/2021 22:36

wan - I'm intrigued by what appear to be parallels between EKF and SourceBio (SBI). Both are in the Chris Mills stable; both have a major involvement, directly or indirectly, in COVID testing; and SBI is known to be a (past or present) customer of EKF, although I'm not sure on what scale. Both are also cash rich. I'd be interested in your thoughts on whether some kind of closer alignment, perhaps even a merger, might make sense.

In passing, I'm also getting rather confused about the different varieties of COVID tests and their respective pros and cons. I'm aware that certain tests are for whether you are infected, others for whether you are immune, but that's about as far as it goes.

You've mentioned e.g. PBS, MTM and ATM, but as a layman I confess that I understand neither how they differ, nor the extent of EKF's competition for any of them - or more accurately, I suppose, for test kits involving any of them. Perhaps others feel the same. Is there an idiot's guide somewhere?

[boadicea] 26/8/2021 21:35

wan - Another platforms show the lock-up TRLS shares in the ISA portfolio annotated as "Lock-up period interim line". I suppose this does not necessarily prove they will be admitted when released although being 'payment' of a deferred dividend I see no reason why not.

[boadicea] 26/8/2021 21:34

wan - Another platforms show the lock-up TRLS shares in the ISA portfolio annotated as "Lock-up period interim line". I suppose this does not necessarily prove they will be admitted when released although being 'payment' of a deferred dividend I see no reason why not.

[tongosti] 26/8/2021 15:26

Tic toc tic toc

[wanttowin] 26/8/2021 13:25

Testing 80p again !

[wan] 26/8/2021 11:55

Relevant post from the Trellus Health thread -

Update...in answer to my complaint to Barclays Smart Investor, part of which was them not showing the Trellus Health 'Entitlements', they have written to me stating they are currently in the process of setting up a line of stock called Trellus Entitlements to enable them to show these new shares.

Smart Investor now shows such entitlements in your ISA as "This product is no longer eligible in ISA" but provides a link into Corporate Actions, where they are shown, including all of the relevant details etc. with the same situation in the SIPP's.

So, let's also hope that the same will apply to the next value enhancement from EKF's relationship with Mount Sinai Innovation Partners.

[wan] 26/8/2021 10:52

Kudos to 1xtrader over on the MyHealthChecked thread for highlighting that Lloyds Pharmacy is now also selling the MyHealthChecked Covid-19 sample collection kit -



Recall that MyHealthChecked Plc (AIM: MHC), signed a Manufacturing Agreement with EKF Diagnostic Holdings plc ("EKF") for PrimeStore® MTM sample collection devices.

[wan] 26/8/2021 10:14

If EKF upgrade Quo-Test so that the FDA clearance includes screening and diagnosis, along with use at point of care e.g. in the doctors office, then that will, in my humble opinion, have a very positive impact on EKF's diabetes revenues. What is also worthy of note, is the indication that Quo-Test is being upgraded to also account for markets outside of the US -

Diabetes is rising worldwide... and is set to rise even further
In 2000, the global estimate of adults living with diabetes was 151 million. By 2009 it had grown by 88% to 285 million. Today, we calculate that 9.3% of adults aged 20–79 years – a staggering 463 million people – are living with diabetes. A further 1.1 million children and adolescents under the age of 20, live with type 1 diabetes.

A decade ago, in 2010, the global projection for diabetes in 2025 was 438 million. With over five years still to go, that prediction has already been surpassed by 25 million.

IDF estimates that there will be 578 million adults with diabetes by 2030, and 700 million by 2045.


I would not goes a far to say that I would drink to that given the complications and consequences of diabetes, but I would raise a glass (of wine!) to EKF for playing their part in addressing and preventing complications and for promoting and aiding healthier outcomes!

[tongosti] 26/8/2021 09:50

Fresh wine in old bottle - get in there fella!

[wan] 26/8/2021 09:22

An item that particularly caught my attention in EKF's Growth Presentation was the launch of Quo-Test A1c Mk II
• Built on existing technology platform with enhanced usability and features. Connectivity wireless and LAN
• Re-engineered casing to reduce effect of dust and temperature extremes
And scheduled for launch in 2022

In the US Quo-Test is FDA cleared, but it is not cleared for screening or diagnosis of diabetes, with the device intended for professional use in a clinical laboratory setting for monitoring long-term glycemic control in individuals previously diagnosed with diabetes.

Interestingly, Quo-Test is one of the products being displayed under the title 'Point of Care' at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo next month -


So, with the upgrade to Quo-Test and the increasing incidence of diabetes firmly in mind, I am hopeful that the use and utility of Quo-Test could be expanded in the US, and thus the following provides further food for thought where at the very least, there will be an increase in the need for monitoring HbA1c and replaces the 2015 recommendation that asymptomatic adults ages 40 to 70 who are overweight or obese should be screened -

August 24/31, 2021
Screening for Prediabetes and Type 2 Diabetes
US Preventive Services Task Force Recommendation Statement

Conclusions and Recommendation The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.

Abstract
Importance An estimated 13% of all US adults (18 years or older) have diabetes, and 34.5% meet criteria for prediabetes. The prevalences of prediabetes and diabetes are higher in older adults. Estimates of the risk of progression from prediabetes to diabetes vary widely, perhaps because of differences in the definition of prediabetes or the heterogeneity of prediabetes. Diabetes is the leading cause of kidney failure and new cases of blindness among adults in the US. It is also associated with increased risks of cardiovascular disease, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis and was estimated to be the seventh leading cause of death in the US in 2017. Screening asymptomatic adults for prediabetes and type 2 diabetes may allow earlier detection, diagnosis, and treatment, with the ultimate goal of improving health outcomes.

Importance
According to the Centers for Disease Control and Prevention 2020 National Diabetes Statistics Report, an estimated 13% of all US adults (18 years or older) have diabetes, and 34.5% meet criteria for prediabetes.1 The prevalence of prediabetes and diabetes are higher in older adults. Of persons with diabetes, 21.4% were not aware of or did not report having diabetes, and only 15.3% of persons with prediabetes reported being told by a health professional that they had this condition.1 Estimates of the risk of progression from prediabetes to diabetes vary widely, perhaps because of differences in the definition of prediabetes or the heterogeneity of prediabetes.2 A large cohort study of 77 107 persons with prediabetes reported that the risk of developing diabetes increased with increasing hemoglobin A1c (HbA1c) level and with increasing body mass index (BMI).3

Diabetes is the leading cause of kidney failure and new cases of blindness among adults in the US. It is also associated with increased risks of cardiovascular disease (CVD), nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis4-6 and was estimated to be the seventh leading cause of death in the US in 2017.1 Screening asymptomatic adults for prediabetes and type 2 diabetes may allow earlier detection, diagnosis, and treatment, with the ultimate goal of improving health outcomes.

Full update -

[tongosti] 25/8/2021 16:00

Such a clever move boy post my last Nov top alert. Really impressed with a few intellectual giants on here.

[faz] 25/8/2021 11:38

I doubt many are waiting because we've filtered him months ago.

[mg1982] 25/8/2021 11:35

come on then Tong....we're all waiting for your impeccable timing comment....

Say that you bought at 75p before it goes too high

[tongosti] 24/8/2021 12:08

Phew - started to get worried about you. Thought you had lost your daily enthusiasm. Welcome back:)

[wan] 24/8/2021 11:05

Still here, and as far as I can, still keeping tabs of things that matter (thanks Mirandaj).....and still invested for the long term (no share sales).

The following is part of the 2021 – 2024 Growth Strategy

21 hours ago
👀 something big is happening -

[tongosti] 24/8/2021 10:28

I notice our pal wan has not posted for days... getting a bit tired maybe?